Cocrystal Pharma, Inc. (FRA:8CC)

Market Cap	11.80M -36.8%
Revenue (ttm)	n/a
Net Income	-8.24M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	0.8200
Previous Close	0.8100
Day's Range	0.8200 - 0.8200
52-Week Range	0.7050 - 2.8000
Beta	n/a
RSI	49.86
Earnings Date	Mar 27, 2026

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemi...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 11
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8CC

Financial Performance

Financial numbers in USD